Compare BioNano Genomics Inc (BNGO) vs Mattel Inc (MAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Mattel Inc — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.66M), while Mattel Inc trades at $15.03 (market cap $4.30B). The key difference: Mattel Inc is far larger — about 314.8× BioNano Genomics Inc's market cap, and Mattel Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MAT | |
|---|---|---|
Market Cap | $13.66M | $4.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $22.16 |
52-Week Low | $1.06 | $13.05 |
Enterprise Value | $16.26M | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Mattel (MAT) trades at $14.74, down 0.34% today, with a bullish technical signal from moving averages and oversold RSI levels. Recent Q2 2026 earnings missed estimates despite 10% revenue growth, reflecting margin pressure from higher costs. The company maintains solid profitability with a 7.78% net margin and attractive valuation at a P/E of 11.22. Cash flow turned negative in 2025 due to increased financing outflows, though operations remain cash-generative.
Outlook is mixed: analyst consensus leans buy (53%) with a $14 price target, but rising expenses and toy market volatility pose risks. The stock's appeal hinges on execution of its entertainment-driven growth strategy and cost management amid economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →
